Still bruised from last week’s Celebrex patent decision, Pfizer is back in the courts trying to keep a generic of its ED drug from hitting the markets before its patent expires in 2019, Bloomberg reports.
The company in this battle is India’s Torrent Pharmaceuticals, which is seeking to tap into Pfizer’s $1.88 billion business.
Bloomberg notes that Torrent is not the first generics maker that it’s taken to court over Viagra, and that the company came to an agreement with Teva which would allow the Israel-based pharmaceutical company to manufacture generic Viagra in the US in 2017 “or earlier under certain circumstances.”
